Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Research Abstract |
We have confirmed that renin-angiotensin system have the potential to Regulate the expression of androgen receptor in prostate cancer cells via in vitro and in vivo experiment. Furthermore, we conducted a clinical study to confirm whether angiotensin II receptor blocker (ARB) would influence the development of prostate cancer .As a result, ARB has the potential to inhibit the expression of androgen receptor through AT1 receptor. Furthermore, clinical study revealed that ARB treatment delayed PSA risingin patients with PSA recurrence after prostatectomy.
|